Should I buy or sell Standard BioTools stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares. View SLGC analyst ratings or view top-rated stocks .

What is Standard BioTools' stock price target for 2024?

3 analysts have issued 1-year target prices for Standard BioTools' stock. Their SLGC share price targets range from $2.30 to $2.50. On average, they predict the company's share price to reach $2.43 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price. View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts .

NASDAQ:SLGC

Standard BioTools (SLGC) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free SLGC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.93
▼
$2.31
50-Day Range: $2.10
▼
$2.83
52-Week Range: $1.73
▼
$3.79

Volume: 33.91 million shs
Average Volume: 10.83 million shs
Market Capitalization: $394.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.43

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Get Standard BioTools alerts:

Standard BioTools MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 15.9% Upside
$2.43 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.59) to ($0.49) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.49 out of 5 stars

2.0

Analyst's Opinion

Consensus Rating
Standard BioTools has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Standard BioTools has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SLGC.

0.0

Dividend Strength

Dividend Yield
Standard BioTools does not currently pay a dividend.
Dividend Growth
Standard BioTools does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLGC.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Standard BioTools this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Standard BioTools insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.90% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
66.35% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Standard BioTools are expected to grow in the coming year, from ($0.59) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Standard BioTools is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Standard BioTools is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Standard BioTools has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

Click here and I’ll show you

About Standard BioTools Stock (NASDAQ:SLGC)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

Ad DTI

Special FREE offer on stock hotsheets

Click here and I’ll show you

SLGC Stock News Headlines

April 18, 2024 | morningstar.com

Standard BioTools Inc LAB

February 25, 2024 | finance.yahoo.com

LAB May 2024 2.500 call

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

January 5, 2024 | finanznachrichten.de

Standard BioTools Inc.: Standard BioTools Stockholders Approve Merger with SomaLogic

January 4, 2024 | finance.yahoo.com

Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting

January 4, 2024 | finance.yahoo.com

Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools

January 3, 2024 | finance.yahoo.com

Proxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools

January 2, 2024 | finance.yahoo.com

SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

January 1, 2024 | markets.businessinsider.com

Boston Millennia Partners To Vote Against Proposed Merger Of SomaLogic With Standard BioTools

December 29, 2023 | finance.yahoo.com

Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

December 29, 2023 | finance.yahoo.com

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

December 29, 2023 | finance.yahoo.com

SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

December 28, 2023 | msn.com

SomaLogic founder, CTO urge shareholders to vote against merger

December 28, 2023 | finance.yahoo.com

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

December 26, 2023 | finance.yahoo.com

SomaLogic Issues Statement Correcting Madryn Asset Management's Misleading Disclosure

December 26, 2023 | finance.yahoo.com

Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives

December 24, 2023 | businesswire.com

Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw “Cautionary Support” for SomaLogic’s Value-Destructive Proposed Merger with Standard BioTools

December 24, 2023 | finance.yahoo.com

Madryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw "Cautionary Support" for SomaLogic’s Value-Destructive Proposed Merger with Standard BioTools

December 22, 2023 | finance.yahoo.com

Tikvah Management Announces Intention to Vote against Somalogic’s Proposed Merger with Standard BioTools

December 22, 2023 | finance.yahoo.com

Madryn Asset Management Reiterates Alternative Path to SomaLogic’s Value-Destructive Proposed Merger with Standard BioTools

December 22, 2023 | finance.yahoo.com

Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools

December 21, 2023 | finance.yahoo.com

Madryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic’s Recent Investor Presentation

December 21, 2023 | finance.yahoo.com

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

December 18, 2023 | businesswire.com

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard ...

December 18, 2023 | finance.yahoo.com

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote "AGAINST" the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

November 22, 2023 | morningstar.com

SomaLogic Inc Class A

See More Headlines

Receive SLGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Business Services
Industry: Commercial physical research
Sub-Industry: N/A
Current Symbol: NASDAQ:SLGC
CUSIP: N/A
CIK: 1837412
Web: ii.cmlifesciencesspac.com
Phone: 303-625-9000
Fax: N/A
Employees: 451
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.43
High Stock Price Target: $2.50
Low Stock Price Target: $2.30
Potential Upside/Downside: +15.9%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-109,160,000.00
Net Margins: -159.54%
Pretax Margin: -159.08%
Return on Equity: -24.72%
Return on Assets: -21.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.79
Quick Ratio: 17.29

Sales & Book Value

Annual Sales: $97.67 million
Price / Sales: 4.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 188,070,000
Free Float: 160,049,000
Market Cap: $394.95 million
Optionable: Optionable
Beta: 1.64

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Stephen A. Williams BS (Age 64)
MB, Ph.D., Chief Medical Officer
Comp: $648.03k
Mr. Adam Taich (Age 49)
Interim CEO
Mr. Pi Zheng (Age 51)
Interim Chief Accounting Officer
Dr. Jason Cleveland Ph.D.
Chief Technology Officer
Dr. Nebojsa Janjic Ph.D. (Age 63)
Chief Science Officer
Mr. Ruben Gutierrez J.D. (Age 49)
General Counsel
Ms. Alison Marie Roelke (Age 49)
Chief People Officer
Dr. Shane Bowen Ph.D.
Chief Research & Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SLGC Stock Analysis - Frequently Asked Questions

Should I buy or sell Standard BioTools stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares.
View SLGC analyst ratings or view top-rated stocks.
What is Standard BioTools' stock price target for 2024?: 3 analysts have issued 1-year target prices for Standard BioTools' stock. Their SLGC share price targets range from $2.30 to $2.50. On average, they predict the company's share price to reach $2.43 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts.

This page (NASDAQ:SLGC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Standard BioTools (SLGC) Stock Price, News & Analysis

Standard BioTools MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Standard BioTools Stock (NASDAQ:SLGC)

SLGC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SLGC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™